{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:08:52Z","timestamp":1792156132991,"version":"4.4.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Global Health Innovative Technology (GHIT) Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Leishmaniasis is a neglected protozoan disease affecting over 12 million people globally with no approved vaccines for human use. New World cutaneous leishmaniasis (CL) caused by <jats:italic>L. mexicana<\/jats:italic> is characterized by the development of chronic non-healing skin lesions. Using the CRISPR\/Cas9 technique, we have generated live attenuated <jats:italic>centrin<\/jats:italic> knockout <jats:italic>L. mexicana (LmexCen<\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup><jats:italic>)<\/jats:italic> parasites. Centrin is a cytoskeletal protein important for cellular division in eukaryotes and, in <jats:italic>Leishmania<\/jats:italic>, is required only for intracellular amastigote replication. We have investigated the safety and immunogenicity characteristics of <jats:italic>LmexCen<\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup> parasites by evaluating their survival and the cytokine production in bone-marrow-derived macrophages (BMDMs) and dendritic cells (BMDCs) in vitro. Our data shows that <jats:italic>LmexCen<\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup> amastigotes present a growth defect, which results in significantly lower parasitic burdens and increased protective cytokine production in infected BMDMs and BMDCs, compared to the wild type (WT) parasites. We have also determined the safety and efficacy of <jats:italic>LmexCen<\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup> in vivo using experimental murine models of <jats:italic>L. mexicana<\/jats:italic>. We demonstrate that <jats:italic>LmexCen<\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup> parasites are safe and do not cause lesions in susceptible mouse models. Immunization with <jats:italic>LmexCen<\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup> is also efficacious against challenge with WT <jats:italic>L. mexicana<\/jats:italic> parasites in genetically different BALB\/c and C57BL\/6 mouse models. Vaccinated mice did not develop cutaneous lesions, displayed protective immunity, and showed significantly lower parasitic burdens at the infection site and draining lymph nodes compared to the control group. Overall, we demonstrate that <jats:italic>LmexCen<\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup> parasites are safe and efficacious against New World cutaneous leishmaniasis in pre-clinical models.<\/jats:p>","DOI":"10.1038\/s41541-022-00449-1","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T11:02:54Z","timestamp":1646218974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Centrin-deficient Leishmania mexicana confers protection against New World cutaneous leishmaniasis"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1112-7715","authenticated-orcid":false,"given":"Greta","family":"Volpedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2741-0942","authenticated-orcid":false,"given":"Thalia","family":"Pacheco-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1368-9858","authenticated-orcid":false,"given":"Erin A.","family":"Holcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5550-712X","authenticated-orcid":false,"given":"Patrick","family":"Lypaczewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Fultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Mishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitenya","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1884-1695","authenticated-orcid":false,"given":"Ryan H.","family":"Huston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail R.","family":"Wharton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranadhir","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subir","family":"Karmakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Oghumu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3881-8337","authenticated-orcid":false,"given":"Shinjiro","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-8220","authenticated-orcid":false,"given":"Sreenivas","family":"Gannavaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira L.","family":"Nakhasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Matlashewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5989-1520","authenticated-orcid":false,"given":"Abhay R.","family":"Satoskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"issue":"Suppl 1","key":"449_CR1","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jinf.2014.07.016","volume":"69","author":"D Pace","year":"2014","unstructured":"Pace, D. Leishmaniasis. J. Infect. 69(Suppl 1), S10\u201318 (2014).","journal-title":"J. Infect."},{"key":"449_CR2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.det.2015.03.018","volume":"33","author":"I Kevric","year":"2015","unstructured":"Kevric, I., Cappel, M. A. & Keeling, J. H. New world and old world Leishmania infections: a practical review. Dermatol. Clin. 33, 579\u2013593 (2015).","journal-title":"Dermatol. Clin."},{"key":"449_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4269\/ajtmh.15-0408","volume":"94","author":"I Okwor","year":"2016","unstructured":"Okwor, I. & Uzonna, J. Social and economic burden of human leishmaniasis. Am. J. Trop. Med. Hyg. 94, 489\u2013493 (2016).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"449_CR4","unstructured":"Center for Disease Control and Prevention. Leishmaniasis. https:\/\/www.cdc.gov\/parasites\/leishmaniasis\/ (2013)."},{"key":"449_CR5","unstructured":"World Health Organization. Leishmaniasis. http:\/\/www.who.int\/leishmaniasis\/en\/ (2018)."},{"key":"449_CR6","doi-asserted-by":"publisher","first-page":"750","DOI":"10.12688\/f1000research.11120.1","volume":"6","author":"E Torres-Guerrero","year":"2017","unstructured":"Torres-Guerrero, E., Quintanilla-Cedillo, M. R., Ruiz-Esmenjaud, J. & Arenas, R. Leishmaniasis: a review. F1000Res. 6, 750 (2017).","journal-title":"F1000Res."},{"key":"449_CR7","doi-asserted-by":"publisher","first-page":"e0005896","DOI":"10.1371\/journal.pntd.0005896","volume":"11","author":"PJ Hotez","year":"2017","unstructured":"Hotez, P. J. Ten failings in global neglected tropical diseases control. PLoS Negl. Trop. Dis. 11, e0005896 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"449_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1353\/hpu.0.0270","volume":"21","author":"A Kealey","year":"2010","unstructured":"Kealey, A. & Smith, R. Neglected tropical diseases: infection, modeling, and control. J. Health Care Poor Underserved 21, 53\u201369 (2010).","journal-title":"J. Health Care Poor Underserved"},{"key":"449_CR9","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1017\/S0031182017000385","volume":"144","author":"P Wolf Nassif","year":"2017","unstructured":"Wolf Nassif, P. et al. Safety and efficacy of current alternatives in the topical treatment of cutaneous leishmaniasis: a systematic review. Parasitology 144, 995\u20131004 (2017).","journal-title":"Parasitology"},{"key":"449_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S1995-7645(12)60084-4","volume":"5","author":"N Singh","year":"2012","unstructured":"Singh, N., Kumar, M. & Singh, R. K. Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pac. J. Trop. Med. 5, 485\u2013497 (2012).","journal-title":"Asian Pac. J. Trop. Med"},{"key":"449_CR11","doi-asserted-by":"crossref","first-page":"815023","DOI":"10.1155\/2015\/815023","volume":"2015","author":"JP de Menezes","year":"2015","unstructured":"de Menezes, J. P., Guedes, C. E., Petersen, A. L., Fraga, D. B. & Veras, P. S. Advances in development of new treatment for leishmaniasis. Biomed. Res. Int. 2015, 815023 (2015).","journal-title":"Biomed. Res. Int"},{"key":"449_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3389\/fmicb.2018.00883","volume":"9","author":"M Mart\u00ednez-L\u00f3pez","year":"2018","unstructured":"Mart\u00ednez-L\u00f3pez, M., Soto, M., Iborra, S. & Sancho, D. Hijacks myeloid cells for immune escape. Front. Microbiol. 9, 883 (2018).","journal-title":"Front. Microbiol."},{"key":"449_CR13","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1128\/IAI.73.4.2101-2108.2005","volume":"73","author":"LU Buxbaum","year":"2005","unstructured":"Buxbaum, L. U. & Scott, P. Interleukin 10- and Fcgamma receptor-deficient mice resolve Leishmania mexicana lesions. Infect. Immun. 73, 2101\u20132108 (2005).","journal-title":"Infect. Immun."},{"key":"449_CR14","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.4049\/jimmunol.171.7.3705","volume":"171","author":"UM Padigel","year":"2003","unstructured":"Padigel, U. M., Alexander, J. & Farrell, J. P. The role of interleukin-10 in susceptibility of BALB\/c mice to infection with Leishmania mexicana and Leishmania amazonensis. J. Immunol. 171, 3705\u20133710 (2003).","journal-title":"J. Immunol."},{"key":"449_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/20477724.2016.1232042","volume":"110","author":"N Maspi","year":"2016","unstructured":"Maspi, N., Abdoli, A. & Ghaffarifar, F. Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review. Pathog. Glob. Health 110, 247\u2013260 (2016).","journal-title":"Pathog. Glob. Health"},{"key":"449_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cellimm.2016.07.010","volume":"309","author":"ND Glennie","year":"2016","unstructured":"Glennie, N. D. & Scott, P. Memory T cells in cutaneous leishmaniasis. Cell. Immunol. 309, 50\u201354 (2016).","journal-title":"Cell. Immunol."},{"key":"449_CR17","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/nm1108","volume":"10","author":"C Zaph","year":"2004","unstructured":"Zaph, C., Uzonna, J., Beverley, S. M. & Scott, P. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat. Med. 10, 1104\u20131110 (2004).","journal-title":"Nat. Med"},{"key":"449_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.pt.2005.06.007","volume":"21","author":"KJ Gollob","year":"2005","unstructured":"Gollob, K. J., Antonelli, L. R. & Dutra, W. O. Insights into CD4+ memory T cells following Leishmania infection. Trends Parasitol. 21, 347\u2013350 (2005).","journal-title":"Trends Parasitol."},{"key":"449_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.molbiopara.2017.06.005","volume":"216","author":"SM Duncan","year":"2017","unstructured":"Duncan, S. M., Jones, N. G. & Mottram, J. C. Recent advances in Leishmania reverse genetics: manipulating a manipulative parasite. Mol. Biochem. Parasitol. 216, 30\u201338 (2017).","journal-title":"Mol. Biochem. Parasitol."},{"key":"449_CR20","doi-asserted-by":"publisher","unstructured":"Zhang, W. W., Lypaczewski, P. & Matlashewski, G. Optimized CRISPR-Cas9 genome editing for leishmania and its use to target a multigene family, induce chromosomal translocation, and study DNA break repair mechanisms. mSphere https:\/\/doi.org\/10.1128\/mSphere.00340-16 (2017).","DOI":"10.1128\/mSphere.00340-16"},{"key":"449_CR21","doi-asserted-by":"publisher","first-page":"e0192723","DOI":"10.1371\/journal.pone.0192723","volume":"13","author":"A Ishemgulova","year":"2018","unstructured":"Ishemgulova, A. et al. CRISPR\/Cas9 in Leishmania mexicana: a case study of LmxBTN1. PLoS ONE 13, e0192723 (2018).","journal-title":"PLoS ONE"},{"key":"449_CR22","doi-asserted-by":"publisher","first-page":"170095","DOI":"10.1098\/rsos.170095","volume":"4","author":"T Beneke","year":"2017","unstructured":"Beneke, T. et al. A CRISPR Cas9 high-throughput genome editing toolkit for kinetoplastids. R. Soc. Open Sci. 4, 170095 (2017).","journal-title":"R. Soc. Open Sci."},{"key":"449_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21360-8","volume":"12","author":"N Baker","year":"2021","unstructured":"Baker, N. et al. Systematic functional analysis of Leishmania protein kinases identifies regulators of differentiation or survival. Nat. Commun. 12, 1244 (2021).","journal-title":"Nat. Commun."},{"key":"449_CR24","doi-asserted-by":"publisher","unstructured":"Shrivastava, R., Tupperwar, N., Drory-Retwitzer, M. & Shapira, M. Deletion of a single LeishIF4E-3 allele by the CRISPR-Cas9 system alters cell morphology and infectivity of Leishmania. mSphere https:\/\/doi.org\/10.1128\/mSphere.00450-19 (2019).","DOI":"10.1128\/mSphere.00450-19"},{"key":"449_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17154-z","volume":"11","author":"WW Zhang","year":"2020","unstructured":"Zhang, W. W. et al. A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing. Nat. Commun. 11, 3461 (2020).","journal-title":"Nat. Commun."},{"key":"449_CR26","doi-asserted-by":"publisher","first-page":"25703","DOI":"10.1074\/jbc.M402794200","volume":"279","author":"A Selvapandiyan","year":"2004","unstructured":"Selvapandiyan, A. et al. Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania. J. Biol. Chem. 279, 25703\u201325710 (2004).","journal-title":"J. Biol. Chem."},{"key":"449_CR27","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/s42003-021-02446-x","volume":"4","author":"S Karmakar","year":"2021","unstructured":"Karmakar, S. et al. Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis. Commun. Biol. 4, 929 (2021).","journal-title":"Commun. Biol."},{"key":"449_CR28","doi-asserted-by":"publisher","unstructured":"Scorza, B. M., Carvalho, E. M. & Wilson, M. E. Cutaneous manifestations of human and murine leishmaniasis. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms18061296 (2017).","DOI":"10.3390\/ijms18061296"},{"key":"449_CR29","doi-asserted-by":"publisher","first-page":"2603730","DOI":"10.1155\/2019\/2603730","volume":"2019","author":"\u00c1 Gabriel","year":"2019","unstructured":"Gabriel, \u00c1. et al. Cutaneous leishmaniasis: the complexity of host\u2019s effective immune response against a polymorphic parasitic disease. J. Immunol. Res. 2019, 2603730 (2019).","journal-title":"J. Immunol. Res."},{"key":"449_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4269\/ajtmh.16-84256","volume":"96","author":"N Aronson","year":"2017","unstructured":"Aronson, N. et al. Diagnosis and treatment of leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am. J. Trop. Med. Hyg. 96, 24\u201345 (2017).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"449_CR31","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/intimm\/dxh313","volume":"17","author":"LE Rosas","year":"2005","unstructured":"Rosas, L. E. et al. Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice. Int. Immunol. 17, 1347\u20131357 (2005).","journal-title":"Int. Immunol."},{"key":"449_CR32","doi-asserted-by":"publisher","first-page":"e3202","DOI":"10.1371\/journal.pntd.0003202","volume":"8","author":"I Contreras","year":"2014","unstructured":"Contreras, I. et al. Impact of Leishmania mexicana infection on dendritic cell signaling and functions. PLoS Negl. Trop. Dis. 8, e3202 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"449_CR33","doi-asserted-by":"publisher","first-page":"8200","DOI":"10.4049\/jimmunol.179.12.8200","volume":"179","author":"AC Hsu","year":"2007","unstructured":"Hsu, A. C. & Scott, P. Leishmania mexicana infection induces impaired lymph node expansion and Th1 cell differentiation despite normal T cell proliferation. J. Immunol. 179, 8200\u20138207 (2007).","journal-title":"J. Immunol."},{"key":"449_CR34","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1046\/j.1440-1711.2001.01014.x","volume":"79","author":"M Rodriguez-Sosa","year":"2001","unstructured":"Rodriguez-Sosa, M., Monteforte, G. M. & Satoskar, A. R. Susceptibility to Leishmania mexicana infection is due to the inability to produce IL-12 rather than lack of IL-12 responsiveness. Immunol. Cell Biol. 79, 320\u2013322 (2001).","journal-title":"Immunol. Cell Biol."},{"key":"449_CR35","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1002\/(SICI)1521-4141(199908)29:08<2524::AID-IMMU2524>3.0.CO;2-H","volume":"29","author":"LM Stamm","year":"1999","unstructured":"Stamm, L. M., Satoskar, A. A., Ghosh, S. K., David, J. R. & Satoskar, A. R. STAT-4 mediated IL-12 signaling pathway is critical for the development of protective immunity in cutaneous leishmaniasis. Eur. J. Immunol. 29, 2524\u20132529 (1999).","journal-title":"Eur. J. Immunol."},{"key":"449_CR36","doi-asserted-by":"publisher","first-page":"294389","DOI":"10.1155\/2010\/294389","volume":"2010","author":"HE Cummings","year":"2010","unstructured":"Cummings, H. E., Tuladhar, R. & Satoskar, A. R. Cytokines and their STATs in cutaneous and visceral leishmaniasis. J. Biomed. Biotechnol. 2010, 294389 (2010).","journal-title":"J. Biomed. Biotechnol."},{"key":"449_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ijpara.2004.10.018","volume":"35","author":"N Bhardwaj","year":"2005","unstructured":"Bhardwaj, N., Rosas, L. E., Lafuse, W. P. & Satoskar, A. R. Leishmania inhibits STAT1-mediated IFN-gamma signaling in macrophages: increased tyrosine phosphorylation of dominant negative STAT1beta by Leishmania mexicana. Int. J. Parasitol. 35, 75\u201382 (2005).","journal-title":"Int. J. Parasitol."},{"key":"449_CR38","doi-asserted-by":"publisher","first-page":"639801","DOI":"10.3389\/fcimb.2021.639801","volume":"11","author":"T Pacheco-Fernandez","year":"2021","unstructured":"Pacheco-Fernandez, T. et al. Revival of leishmanization and leishmanin. Front. Cell Infect. Microbiol 11, 639801 (2021).","journal-title":"Front. Cell Infect. Microbiol"},{"key":"449_CR39","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jmii.2015.05.007","volume":"50","author":"M Rostamian","year":"2017","unstructured":"Rostamian, M., Sohrabi, S., Kavosifard, H. & Niknam, H. M. Lower levels of IgG1 in comparison with IgG2a are associated with protective immunity against Leishmania tropica infection in BALB\/c mice. J. Microbiol. Immunol. Infect. 50, 160\u2013166 (2017).","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"449_CR40","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/01.shk.0000142249.08135.e9","volume":"22","author":"H Watanabe","year":"2004","unstructured":"Watanabe, H., Numata, K., Ito, T., Takagi, K. & Matsukawa, A. Innate immune response in Th1- and Th2-dominant mouse strains. Shock 22, 460\u2013466 (2004).","journal-title":"Shock"},{"key":"449_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0020-7519(79)90062-6","volume":"9","author":"H P\u00e9rez","year":"1979","unstructured":"P\u00e9rez, H., Labrador, F. & Torrealba, J. W. Variations in the response of five strains of mice to Leishmania mexicana. Int. J. Parasitol. 9, 27\u201332 (1979).","journal-title":"Int. J. Parasitol."},{"key":"449_CR42","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0022-1759(98)00015-5","volume":"212","author":"RM Martin","year":"1998","unstructured":"Martin, R. M., Brady, J. L. & Lew, A. M. The need for IgG2c specific antiserum when isotyping antibodies from C57BL\/6 and NOD mice. J. Immunol. Methods 212, 187\u2013192 (1998).","journal-title":"J. Immunol. Methods"},{"key":"449_CR43","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","volume":"172","author":"J Mestas","year":"2004","unstructured":"Mestas, J. & Hughes, C. C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731\u20132738 (2004).","journal-title":"J. Immunol."},{"key":"449_CR44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-1-0716-0294-2_14","volume":"2116","author":"WW Zhang","year":"2020","unstructured":"Zhang, W. W., Lypaczewski, P. & Matlashewski, G. Application of CRISPR\/Cas9-Mediated Genome Editing in Leishmania. Methods Mol. Biol. 2116, 199\u2013224 (2020).","journal-title":"Methods Mol. Biol."},{"key":"449_CR45","doi-asserted-by":"publisher","first-page":"6967","DOI":"10.4049\/jimmunol.167.12.6967","volume":"167","author":"JE Uzonna","year":"2001","unstructured":"Uzonna, J. E., Wei, G., Yurkowski, D. & Bretscher, P. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J. Immunol. 167, 6967\u20136974 (2001).","journal-title":"J. Immunol."},{"key":"449_CR46","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4103\/0974-777X.62876","volume":"2","author":"S Nyl\u00e9n","year":"2010","unstructured":"Nyl\u00e9n, S. & Gautam, S. Immunological perspectives of leishmaniasis. J. Glob. Infect. Dis. 2, 135\u2013146 (2010).","journal-title":"J. Glob. Infect. Dis."},{"key":"449_CR47","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/ni725","volume":"2","author":"T Biedermann","year":"2001","unstructured":"Biedermann, T. et al. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB\/c mice. Nat. Immunol. 2, 1054\u20131060 (2001).","journal-title":"Nat. Immunol."},{"key":"449_CR48","first-page":"54.52","volume":"200","author":"G Prajwal","year":"2018","unstructured":"Prajwal, G. & Poudel, B. IL-4 signaling is required for optimal Th1 responses during Leishmania major infection. J. Immunol. 200, 54.52 (2018).","journal-title":"J. Immunol."},{"key":"449_CR49","doi-asserted-by":"publisher","first-page":"e1003699","DOI":"10.1371\/journal.ppat.1003699","volume":"9","author":"R Hurdayal","year":"2013","unstructured":"Hurdayal, R. et al. Deletion of IL-4 receptor alpha on dendritic cells renders BALB\/c mice hypersusceptible to Leishmania major infection. PLoS Pathog. 9, e1003699 (2013).","journal-title":"PLoS Pathog."},{"key":"449_CR50","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1002\/1521-4141(2002010)32:10<2923::AID-IMMU2923>3.0.CO;2-E","volume":"32","author":"J Alexander","year":"2002","unstructured":"Alexander, J. et al. An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection. Eur. J. Immunol. 32, 2923\u20132933 (2002).","journal-title":"Eur. J. Immunol."},{"key":"449_CR51","doi-asserted-by":"publisher","first-page":"e930","DOI":"10.1371\/journal.pntd.0000930","volume":"5","author":"KJ Bryson","year":"2011","unstructured":"Bryson, K. J. et al. BALB\/c mice deficient in CD4 T cell IL-4R\u03b1 expression control Leishmania mexicana Load although female but not male mice develop a healer phenotype. PLoS Negl. Trop. Dis. 5, e930 (2011).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"449_CR52","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1128\/iai.63.12.4894-4899.1995","volume":"63","author":"A Satoskar","year":"1995","unstructured":"Satoskar, A., Bluethmann, H. & Alexander, J. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect. Immun. 63, 4894\u20134899 (1995).","journal-title":"Infect. Immun."},{"key":"449_CR53","first-page":"Unit 19.12","volume":"Chapter 19","author":"DL Sacks","year":"2001","unstructured":"Sacks, D. L. & Melby, P. C. Animal models for the analysis of immune responses to leishmaniasis. Curr. Protoc. Immunol. Chapter 19, Unit 19.12 (2001).","journal-title":"Curr. Protoc. Immunol."},{"key":"449_CR54","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12026-008-8074-5","volume":"42","author":"LU Buxbaum","year":"2008","unstructured":"Buxbaum, L. U. A detrimental role for IgG and FcgammaR in Leishmania mexicana infection. Immunol. Res. 42, 197\u2013209 (2008).","journal-title":"Immunol. Res."},{"key":"449_CR55","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1046\/j.1523-1755.1999.00369.x","volume":"55","author":"SR Holdsworth","year":"1999","unstructured":"Holdsworth, S. R., Kitching, A. R. & Tipping, P. G. Th1 and Th2 T helper cell subsets affect patterns of injury and outcomes in glomerulonephritis. Kidney Int. 55, 1198\u20131216 (1999).","journal-title":"Kidney Int"},{"issue":"Pt 2","key":"449_CR56","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1017\/S0031182000074102","volume":"105","author":"PA Bates","year":"1992","unstructured":"Bates, P. A., Robertson, C. D., Tetley, L. & Coombs, G. H. Axenic cultivation and characterization of Leishmania mexicana amastigote-like forms. Parasitology 105(Pt 2), 193\u2013202 (1992).","journal-title":"Parasitology"},{"key":"449_CR57","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1016\/j.vaccine.2014.05.009","volume":"32","author":"A Selvapandiyan","year":"2014","unstructured":"Selvapandiyan, A. et al. Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis. Vaccine 32, 3895\u20133901 (2014).","journal-title":"Vaccine"},{"key":"449_CR58","doi-asserted-by":"publisher","first-page":"D457","DOI":"10.1093\/nar\/gkp851","volume":"38","author":"M Aslett","year":"2010","unstructured":"Aslett, M. et al. TriTrypDB: a functional genomic resource for the Trypanosomatidae. Nucleic Acids Res. 38, D457\u2013462 (2010).","journal-title":"Nucleic Acids Res"},{"key":"449_CR59","unstructured":"Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv. https:\/\/arxiv.org\/pdf\/1303.3997.pdf (2013)."},{"key":"449_CR60","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The Sequence Alignment\/Map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"449_CR61","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841\u2013842 (2010).","journal-title":"Bioinformatics"},{"key":"449_CR62","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ajpath.2021.01.012","volume":"191","author":"S Varikuti","year":"2021","unstructured":"Varikuti, S., Verma, C., Natarajan, G., Oghumu, S. & Satoskar, A. R. MicroRNA155 plays a critical role in the pathogenesis of cutaneous leishmania major infection by promoting a Th2 response and attenuating dendritic cell activity. Am. J. Pathol. 191, 809\u2013816 (2021).","journal-title":"Am. J. Pathol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00449-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00449-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00449-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T14:34:47Z","timestamp":1669300487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00449-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["449"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00449-1","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,2]]},"assertion":[{"value":"13 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The FDA is currently a co-owner of two US patents that claim attenuated <i>Leishmania<\/i> species with the <i>centrin<\/i> gene deletion (US7,887,812 and US 8,877,213). This article reflects the views of the authors and should not be construed to represent FDA\u2019s views or policies. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}